Council and Parliament agree on new rules to enhance efficiency in pharmaceutical sector
The Council of the EU and the European Parliament have reached a provisional agreement on reforming the EU’s pharmaceutical framework, focusing on patient access, regulatory efficiency, industry competitiveness, and medicinal supply security, with incentives to address antimicrobial resistance. Under the agreement, new medicines will receive eight years of data exclusivity and one year of market protection post-authorisation and Article 56a will allow Member States to require sufficient medicine supplies to meet national demands. The EU pharma package will also expand activities for generic/biosimilar manufacturers for market entry post-IP rights expiry, including procurement tenders and introduce a transferrable exclusivity voucher, granting one extra year of protection for developing priority antimicrobials, among other things. The provisional agreement will need to be endorsed by the Council and Parliament, before it is formally adopted and published in the Official Journal of the EU.